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Purpose: To investigate whether seasonal modification in the concentration of atropine 
drops is effective in retarding the progression of myopia.
Methods: Two hundred and forty eyes of 120 healthy preschool- and school-age 
children in Chiayi region, Taiwan were recruited. The treatment group consisted 
of 126 eyes of 63 children who received atropine eye drops daily for one year and 
the control group included 114 eyes of 57 children who received nothing. The 
concentration of atropine eye drops was modified by seasonal variation as follows: 
0.1% for summer, 0.25% for spring and fall, and 0.5% for winter. Refractive error, 
visual acuity, intraocular pressure (IOP), and axial length were evaluated before and 
after intervention.
Results: Mean age was 9.1±2.8 years in the atropine group versus 9.3±2.8 years in 
controls (P=0.88). Mean spherical equivalent, refractive error and astigmatism were 
-1.90±1.66 diopters (D) and -0.50±0.59 D in the atropine group; corresponding values 
in the control group were -2.09±1.67 D (P=0.97) and -0.55±0.60 D (P=0.85), respectively. 
After one year, mean progression of myopia was 0.28±0.75 D in the atropine group 
vs 1.23±0.44 D in controls (P<0.001). Myopic progression was significantly correlated 
with an increase in axial length in both atropine (r=0.297, P=0.001) and control 
(r=0.348, P<0.001) groups. No correlation was observed between myopic progression 
and IOP in either study group.
Conclusion: Modifying the concentration of atropine drops based on seasonal 
variation, seems to be effective and tolerable for retarding myopic progression in 
preschool- to school-age children.
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INTRODUCTION
Myopia is a common ocular disorder, and 
high or pathologic myopia (greater than 6 
diopters) is associated with potentially blinding 
complications, such as macular degeneration, 
retinal detachment, glaucoma and cataracts.1-4 
The prevalence of myopia in young adults in 
Taiwan, Hong Kong, and Singapore (60% to 
80%) is higher than that in the United States 
and Europe (20% to 50%).1,5-7 Data released 
by the Taiwanese National Health Bureau in 
2003 showed that the prevalence of myopia in 
preschool children aged 4-5 years, 5-6 years 
and 6-7 years was 11.36%, 15.18% and 18.84%, 
respectively.8 Corresponding figures based on Retarding Myopia with Atropine; Lu and Chen
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data in 1991-1994 had been 4.79%, 5.68% and 
7.34%, respectively.8 Therefore myopia appears 
to be an important and increasing national 
health issue in Taiwan.
The rate of myopia progression is highest 
in young children and the average age for 
stabilization of myopia is approximately 16 
years.1 The earlier the onset of myopia, the 
more rapid its progression. Therefore, the value 
of any treatment capable of slowing down or 
arresting the progression of myopia cannot 
be overemphasized. The etiopathogenesis of 
myopia might include a genetic basis, excessive 
accommodation, prolonged near work, and 
proliferation of chondrocytes on the anterior 
margins of the sclera.7, 9-12 
  Among current therapeutic modalities 
used for treatment of myopia, atropine eye 
drops have been reported to retard myopia 
progression in three randomized clinical 
trials.13-15 Three different concentrations of 
atropine (0.1%, 0.25%, 0.5%) all significantly 
reduced myopia progression, with 0.5% 
atropine being the most effective.15 However, 
photophobia and poor compliance, especially 
with the highest concentration (0.5%), are 
drawbacks to such treatment.16 We, therefore, 
hypothesized that adjusting the concentration 
of atropine (i.e. 0.1%, 0.25%, and 0.5%), based 
on seasonal variation, sunlight intensity 
and myopia severity, may provide better 
physiological adaptation for preschool- and 
school-age children receiving myopia therapy 
particularly for subjects living close to the 
Tropic of Cancer such as the Chiayi region in 
Taiwan, or in areas of low latitude.
METHODS
This study was a university-based, case-
control study including 240 eyes of 120 
healthy preschool and school-age children 
from October 2006 to December 2008 in Chiayi 
area, Taiwan. The target population included 
all pre-school and school aged students. 
Children with previous ocular trauma, 
traumatic cataracts, keratoconus, high myopia 
(-10 diopters [D] or higher), high hyperopia 
(>+3.0D), severe astigmatism (>-3.0D), ocular 
hypertension, or glaucoma were excluded. 
Subjects who received complete atropine 
treatment more than one year were included. 
The control subjects consisted of children who 
had received no medication for more than 
one year. The treatment group included 126 
eyes of 63 children who received atropine eye 
drops, one drop in each eye for one year; 114 
eyes of 57 children who received no treatment 
served as controls. 
The concentration of atropine eye drops 
(0.1%, 0.25%, and 0.5%) was modified by 
seasonal variation, sunlight intensity and 
severity of myopia. In general, the 0.1% dilution 
was used in summer, the 0.25% dosage in 
spring and fall, and the 0.5% concentration in 
winter. For those who had myopia < -0.50D and 
were less than 7 years of age, 0.5% atropine 
was not applied. The frequency of instillation 
was reduced to twice weekly for very low 
myopes (-0.75 to 0 D). Anti-UV sunglasses 
were prescribed for subjects who had outdoor 
activities and progressive spectacles were 
given for children who had difficulty in the 
classroom. 
Initial ocular examinations included 
uncorrected visual acuity (UCVA), measurement 
of refractive errors, best-spectacle corrected 
visual acuity (BSCVA), intraocular pressure 
(IOP) and axial length (AL) measurements, all 
of which were repeated during prescheduled 
visits every four to six weeks. Refraction was 
measured at baseline under cycloplegia (1% 
tropicamide) and refractions during the study 
or at final follow-up were obtained under the 
effect of atropine. We collected data at three-
month intervals for statistical analysis. 
Statistical analysis was performed using 
standard software (SPSS, version 11.01 
for Windows, SPSS Corp., Chicago, USA). 
Student’s t-test and correlation coefficients 
were used for statistical analysis. Ninety-five 
percent confidence intervals were calculated to 
compare mean values. P<0.05 was considered 
as statistically significant.
RESULTS
Mean age was 9.1±2.8 (range, 4-16) years in Retarding Myopia with Atropine; Lu and Chen
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the atropine group versus 9.3±2.8 (range, 
4-16) years in the control group (P=0.88). 
At baseline, mean spherical equivalent (SE) 
refractive error was -1.90±1.66 (range 0 to 
-7.63) D and mean astigmatism was -0.50±0.59 
(range, 0 to -2.50) D in the atropine group. 
Corresponding values in the control group 
were -2.09±1.67 (range, 0 to -7.50) D (P=0.969) 
and -0.55±0.60 (range 0 to -2.50) D (P=0.854), 
respectively (Figures 1A and 1B). After one 
year, mean myopia progression was 0.28±0.75 
D versus 1.23±0.44 D in the treatment and 
control groups respectively (P < 0.001) (Table 1, 
Figures 2 and 3).
(A) (B)
Figure 1. Distribution of myopia in the atropine (A, 126 eyes) and control (B, 114 eyes) groups at baseline.
(A) (B)
Figure 2. Changes in spherical equivalent refractive error in the atropine (A) and control (B) groups.Retarding Myopia with Atropine; Lu and Chen
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Mean  axial  length  at  baseline  was 
23.78±0.94 mm and 23.92±0.83 mm in the 
atropine and control groups, respectively 
(P=0.129). Corresponding figures one year 
later were 24.12±0.99 mm and 24.78± 0.96 mm, 
respectively (P<0.001). Progression of myopia 
was significantly correlated with an increase 
in axial length in both the atropine (r=0.297, 
P=0.001) and control (r=0.348, P<0.001) groups 
as shown in Figure 4.
Baseline mean IOP was 17.39±3.97 and 
17.89±3.48 mmHg (P=0.340) in the atropine 
and control groups, respectively which 
reached 18.06±3.37 and 18.14±3.29 mmHg 
(P=0.855) at final follow-up, respectively. The 
progression of myopia was not correlated with 
IOP increase in the atropine group (r=0.0023, 
P=0.907) or in the controls (r=0.001, P=0.907) 
as shown in Figure 5A. The progression of 
myopia was also not correlated with raw IOP 
values (r=-0.0015, P=0.923) as demonstrated 
in Figure 5B.
Adverse events such as papillae, follicles, 
subjective decrease in visual acuity, and 
difficulty in accommodation, were mild in 
severity. No serious adverse effects were 
reported.
(A) (B)
Figure 3. 95% confidence intervals (CI) for spherical equivalent refractive error in the atropine (A) and control (B) 
groups.
Mean SD Min Max
Treatment group 
Baseline −1.90 1.66 −7.63 0
3 months −1.92 1.68 −7.63 0.19
6 months −1.98 1.84 −8.38 1.25
9 months −2.04 1.80 −8.38 0.63
12 months −2.17 1.88 −8.25 0.75
Controls
Baseline −2.09 1.67 −7.50 -0.250
6 months −2.86 1.76 −8.50 -1.00
12 months −3.32 1.79 −8.88 -1.25
Table 1. Spherical equivalent refractive error (diopters) 
in the study groups
SD, standard deviation; Min, minimum; Max, maximum.
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Figure 4.  Correlation  between  progression  of  myopia 
and increase in axial length in the study groups.Retarding Myopia with Atropine; Lu and Chen
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DISCUSSION
In an evidence-based review article, Saw 
et al17 reported no evidence supporting the 
effect of bifocal lenses, pressure-lowering eye 
drops, or soft contact lenses on retarding the 
progression of myopia. Only atropine eye drops 
were supported by levels B and I evidence 
(B, moderately important recommendation; I, 
strong evidence supporting recommendation) 
and were very cost-effective in this regard. 
Although treatment with 0.5% atropine was 
the most effective,15 children and parents 
usually refrained from such treatment owing 
to adverse effects, especially photophobia 
in strong sunlight. In our series, the mean 
annual progression of myopia (0.28±0.75D) 
with varying concentrations (0.1%, 0.25%, and 
0.5%) of atropine based on seasonal variation 
and sunlight intensity, was greater than that of 
treatment with 0.5% atropine (0.04±0.63D), but 
less than that of 0.25% atropine (0.45±0.55D) 
or 0.1% atropine (0.47±0.91D) as reported 
by Shin and Chen.15 Therefore, adjusting the 
concentration of atropine is highly effective, 
especially in regions with full sunshine, such 
as areas close to the Tropic of Cancer or regions 
of low latitude. 
Atropine, a muscarinic antagonist, acts by 
paralyzing accommodation and has a direct 
effect on scleral growth.18,19 Our results revealed 
that progression of myopia was significantly 
correlated with an increase in axial length. We 
thus might attribute the retardation of myopia to 
the slowed rate of scleral growth. Adverse effects 
of atropine include photophobia, subjectively 
decreased visual acuity, abnormalities of 
accommodation, macular degeneration, retinal 
toxicity, and cataract formation due to excessive 
ultraviolet light.20-21 We therefore prescribed 
anti-UV sunglasses and suggested wearing 
a sunscreen hat for patients with outdoor 
activities.
Siatkowski et al22 for the US Pirenzepine 
Study Group and Tan et al23 for the Asian 
Pirenzepine Study Group reported that 2% 
pirenzepine ophthalmic gel, a subtype selective 
M1 anti-muscarinic agent, used twice daily was 
associated with less increase in myopia, 0.26 D 
and 0.47 D respectively, over a 1-year treatment 
period as compared to their placebo-controlled 
groups who demonstrated mean increase in 
myopia of 0.53 D and 0.84 D, respectively. Chua 
et al24 in Singapore used 1% atropine to treat 
myopia and reported that myopia progression 
was only -0.28±0.92 D per year in the treated 
group as compared to -1.20±0.69 D per year 
in the placebo-controlled group. Fan et al25 
in Hong Kong used topical 1% atropine eye 
ointment to treat myopia and reported that 
myopic progression was significantly less in 
the atropine group (+0.06±0.79 D) than in the 
(A)
Figure 5A. Correlation between progression of myopia 
and increase in intraocular pressure in the study groups.
(B)
Figure 5B. Correlation between progression of myopia 
and intraocular pressure in all subjects.Retarding Myopia with Atropine; Lu and Chen
80 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2010; Vol. 5, No. 2
control group (-1.19±2.48 D). 
Most children or their parents suspend 
treatment in summer if high concentrations 
of atropine (0.5% or 1%) are prescribed. 
We probed other reasons patients gave up 
therapy which included irritation from eye 
drops, high expectations for myopia control, 
misunderstanding or incomplete education, and 
too much time spent for ocular examinations. 
By providing better physiologic adaptation, 
one may be able to improve such treatment. To 
improve compliance, we reduced the frequency 
of instillation to twice weekly for very low 
myopes (-0.75 to 0 D). Anti-UV sunglasses 
were prescribed for subjects who had outdoor 
activities and progressive spectacles (trifocal or 
bifocal) were given for those who had difficulty 
in the classroom or for reading. Trifocal lenses, 
not bifocals, had a better cosmetic appearance 
and was preferred by children. 
It remains a myth that some subjects may 
achieve significant improvement or reduction 
in established myopia with atropine therapy. 
For example, in this study, myopia of -1.25 D 
regressed to emmetropia or -2.50 D improved 
to -1.0 D, after three to six months of atropine 
treatment and remained stabilized thereafter. 
One previous study on intraocular pressure 
lowering eye drops showed no effect on 
retarding myopia progression.26 Our results 
also showed that progression of myopia was 
not correlated with IOP.
In our study axial length appeared to 
increase only minimally after continuous 
atropine therapy for more than one year. This 
effect may be attributed to increased scleral 
rigidity or slower scleral growth. We also have 
to consider the phenomenon of pseudomyopia 
that is the power difference before and 
after cycloplegia in the clinic, because the 
mydriatic agent might not completely paralyze 
accommodation. More cases are needed to 
elucidate this issue. 
We hypothesize the “trigger theory” such 
that children born by high myopic parents are 
like a pistol loaded with bullets (the genome) 
that might not do any harm if not triggered (by 
risk factors); but a lot of damage (complications) 
might follow if the triggers are pulled again 
and again. Atropine acts as a viscous medium 
to dampen or slow down such bullets thus 
reducing the damage. 
In Singapore, Tong et al27 reported that 
after stopping treatment, eyes treated with 
atropine demonstrated higher rates of myopia 
progression as compared to eyes treated with 
placebo. However, absolute myopia progression 
after 3 years was significantly lower in the 
atropine group as compared to controls. We 
thus strongly suggest that myopia should be 
treated intensively and as early as possible in 
order to avoid late complications caused by 
high myopia. The current study demonstrated 
that by improving compliance to the medication 
and reducing complaints of photophobia, 
the modified use of atropine concentrations 
of 0.1%, 0.25%, and 0.5%, based on seasonal 
variation and severity of myopia, effectively 
delayed myopia progression in preschool and 
school-age children. Therefore in subjects with 
low to moderate myopia, atropine appears to 
significantly retard the progression of myopia. 
Whether pathologic or extreme myopia could 
be prevented by the use of atropine requires 
a large scale longitudinal study.
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